Any feedback?
Please rate this page
(search_result.php)
(0/150)

BRENDA support

Refine search

Search Source Tissue

show results
Don't show organism specific information (fast!)
Search organism in taxonomic tree (slow, choose "exact" as search mode, e.g. "mammalia" for rat,human,monkey,...)
(Not possible to combine with the first option)
Refine your search
Show additional data
do not include text mining results
include AMENDA results (Automatic Mining of Enzyme Data)

Search term: blood serum

Results 1 - 100 of 165 > >>
download as CSV
download all results as CSV
EC Number Recommended Name Source Tissue Commentary Reference
Show all pathways known for 1.1.1.1Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.1alcohol dehydrogenase blood serum among all tested classes of ADH isoenzymes, only class I has higher activity in serum of patients with breast cancer in stage IV. The total ADH activity is not significantly higher in patients with breast cancer than in healthy controls. The changes in activity, especially in class I ADH, appear to be caused by isoenzymes being released from the organ damaged by metastatic disease 669630
Show all pathways known for 1.1.1.1Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.1alcohol dehydrogenase blood serum the total ADH activity is significantly higher (44%) among patients with cancer than healthy ones. The activity of class I ADH isoenzymes is elevated only in the serum of patients with metastatic liver cancer. This increase of activity seems to be caused by the enzyme released from liver cancer cells and primary tumors originating in other organs 687976
Show all pathways known for 1.1.1.27Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.27L-lactate dehydrogenase blood serum the level of L-lactate dehydrogenase B are specifically increased in non-small cell lung cancer 670115
Show all pathways known for 1.1.1.28Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.28D-lactate dehydrogenase blood serum - -, 740891
Display the word mapDisplay the reaction diagram Show all sequences 1.10.3.3L-ascorbate oxidase blood serum - 765849
Show all pathways known for 1.11.1.6Display the word mapDisplay the reaction diagram Show all sequences 1.11.1.6catalase blood serum catalase activity is significantly higher in patients with renal cell carcinoma than in controls 758318
Show all pathways known for 1.11.1.9Display the word mapDisplay the reaction diagram Show all sequences 1.11.1.9glutathione peroxidase blood serum - 764515
Display the word mapDisplay the reaction diagram Show all sequences 1.14.11.4procollagen-lysine 5-dioxygenase blood serum - 722865
Show all pathways known for 1.14.17.1Display the word mapDisplay the reaction diagram Show all sequences 1.14.17.1dopamine beta-monooxygenase blood serum - 438631, 438632, 703268
Show all pathways known for 1.14.17.1Display the word mapDisplay the reaction diagram Show all sequences 1.14.17.1dopamine beta-monooxygenase blood serum activity is highest in 5-day-old rats, it decreases till the age of 14 days and increases mainly in 14-day to 35-day-old animals, significant decrease in activity in rats between 35 to 40 days, adult rats aged 90-120 days show a stable activity of dopamine bet-hydroxylase 660083
Show all pathways known for 1.14.17.1Display the word mapDisplay the reaction diagram Show all sequences 1.14.17.1dopamine beta-monooxygenase blood serum enzyme activity in children and adolescents increases with the age between 3-10 years, later it decreases approximately by the age of 10-14 years. At the age of 21 to 60 years the dopamine-beta-hydroxylase level is stable 660083
Display the word mapDisplay the reaction diagram Show all sequences 1.14.19.3acyl-CoA 6-desaturase blood serum - 745488
Show all pathways known for 1.14.19.30Display the word mapDisplay the reaction diagram Show all sequences 1.14.19.30acyl-lipid (8-3)-desaturase blood serum - 745488, 745593
Show all pathways known for 1.16.3.1Display the word mapDisplay the reaction diagram Show all sequences 1.16.3.1ferroxidase blood serum - -, 744016, 744470
Show all pathways known for 1.4.3.21Display the word mapDisplay the reaction diagram Show all sequences 1.4.3.21primary-amine oxidase blood serum decreased SSAO serum activity in schizophrenic patients treated with second generation antipsychotics known to disturb glucose metabolism 686502
Show all pathways known for 1.4.3.21Display the word mapDisplay the reaction diagram Show all sequences 1.4.3.21primary-amine oxidase blood serum reduced enzyme activity is found in haemodialysed uremic patients before and after dialysis treatment, compared to controls. The activity is slightly lower in peritoneally dialysed, and normal in not dialysed patients. In haemodialysed patients SSAO activity is elevated compared to controls 688488
Show all pathways known for 1.4.3.21Display the word mapDisplay the reaction diagram Show all sequences 1.4.3.21primary-amine oxidase blood serum treatment with benzylamine + vanadate reduces the elevated serum SSAO activity, decreases the accumulation of advanced-glycation end products and increases the bioavailability of nitric oxide in diabetic animals, similarly to insulin 688489
Show all pathways known for 1.4.3.22Display the word mapDisplay the reaction diagram Show all sequences 1.4.3.22diamine oxidase blood serum - 686654, 701603
Show all pathways known for 1.4.3.22Display the word mapDisplay the reaction diagram Show all sequences 1.4.3.22diamine oxidase blood serum a significantly lower serum diamine oxidase is found in the pseudoallergy group compared with the allergy group 763860
Show all pathways known for 1.4.3.22Display the word mapDisplay the reaction diagram Show all sequences 1.4.3.22diamine oxidase blood serum mean/median concentrations are between 0.5 and 1.5 ng/ml in healthy volunteers (n=58) and mastocytosis patients (n=19) and plateau at approximately 145 ng/ml during pregnancy 764513
Show all pathways known for 1.4.3.22Display the word mapDisplay the reaction diagram Show all sequences 1.4.3.22diamine oxidase blood serum the mean activity is 7.59 U/l for women and 2.38 U/l for men. Gender is a major determinant for DAO activity in healthy subjects 686129
Show all pathways known for 1.4.3.22Display the word mapDisplay the reaction diagram Show all sequences 1.4.3.22diamine oxidase blood serum variant ABP1 alleles leading to the amino-acid substitutions Thr16Met, Ser332Phe and His645Asp are identified with frequencies of 25.4, 6.3 and 30.6%, respectively. Over 70% of the population carry at least one amino-acid substitution. Individuals carrying the 645Asp amino acid display lower serum diamine oxidase activity as compared with noncarriers with a significant gene-dose effect. This is due to an increase in the Michaelis-Menten constant. Individuals heterozygous for 645Asp show Vmax/Km values of 66% and homozygous 51% as compared with noncarriers. The effect of the 16Met variant allele is lower and that of the rarest allele 332Phe is negligible 689356
Show all pathways known for 1.4.3.3Display the word mapDisplay the reaction diagram Show all sequences 1.4.3.3D-amino-acid oxidase blood serum - 763710
Show all pathways known for 1.4.3.4Display the word mapDisplay the reaction diagram Show all sequences 1.4.3.4monoamine oxidase blood serum no significant gender-related difference in SSAO activity 689723
Display the word mapDisplay the reaction diagram Show all sequences 1.4.4.2glycine dehydrogenase (aminomethyl-transferring) blood serum - 763473
Show all pathways known for 2.1.1.5Display the word mapDisplay the reaction diagram Show all sequences 2.1.1.5betaine-homocysteine S-methyltransferase blood serum - 733463, 733673
Show all pathways known for 2.1.3.3Display the word mapDisplay the reaction diagram Show all sequences 2.1.3.3ornithine carbamoyltransferase blood serum - 756979
Display the word mapDisplay the reaction diagram Show all sequences 2.3.2.13protein-glutamine gamma-glutamyltransferase blood serum enhanced serum immunoreactivity to tTG-2 antigens in some patients with multiple myeloma 685824
Show all pathways known for 2.3.2.2Display the word mapDisplay the reaction diagram Show all sequences 2.3.2.2gamma-glutamyltransferase blood serum - 684743, 684787, 686110, 686301, 687153
Show all pathways known for 2.3.2.2Display the word mapDisplay the reaction diagram Show all sequences 2.3.2.2gamma-glutamyltransferase blood serum association between serum gamma-glutamyltransferase and type 2 diabetes 686319
Show all pathways known for 2.3.2.2Display the word mapDisplay the reaction diagram Show all sequences 2.3.2.2gamma-glutamyltransferase blood serum association between serum gamma-glutamyltransferase levels and coronary microvascular function in hypertensive patients 688145
Show all pathways known for 2.3.2.2Display the word mapDisplay the reaction diagram Show all sequences 2.3.2.2gamma-glutamyltransferase blood serum associations of gamma-glutamyltransferase with fasting glucose and HbA1c are stronger in women with diabetes compared to women without diabetes. gamma-Gutamyltransferase is associated with fasting insulin to the same extent in all women, irrespective of diabetes status. Results excluding hyperinsulinemic women, i.e., in the highest fourth of the fasting insulin distribution, are similar to those obtained for all non-diabetic women as are results excluding women in the highest quartile of the alcohol consumption distribution and for women with alanine aminotransferase and gamma-glutamyltransferase levels within the normal range 687004
Show all pathways known for 2.3.2.2Display the word mapDisplay the reaction diagram Show all sequences 2.3.2.2gamma-glutamyltransferase blood serum elevated gamma-glutamyltransferase is associated with significantly increased risk of stroke, fatal coronary heart disease events and cardiovascular disease mortality independent of established cardiovascular disease risk factors and may be a useful additional marker for long-term cardiovascular disease 695962
Show all pathways known for 2.3.2.2Display the word mapDisplay the reaction diagram Show all sequences 2.3.2.2gamma-glutamyltransferase blood serum gamma-glutamyltransferase can be used as a marker related with oxidative stress 687000
Show all pathways known for 2.3.2.2Display the word mapDisplay the reaction diagram Show all sequences 2.3.2.2gamma-glutamyltransferase blood serum gamma-glutamyltransferase is associated with mortality in both men and women, especially in patients younger than 30 years. Even high-normal gamma-glutamyltransferase is a risk factor for all-cause mortality 686321
Show all pathways known for 2.3.2.2Display the word mapDisplay the reaction diagram Show all sequences 2.3.2.2gamma-glutamyltransferase blood serum gamma-glutamyltransferase is independently associated with an increased level of C-reactive protein in both males and females. In addition, in males, gamma-glutamyltransferase is related to an increased level of arterial stiffness 689280
Show all pathways known for 2.3.2.2Display the word mapDisplay the reaction diagram Show all sequences 2.3.2.2gamma-glutamyltransferase blood serum gamma-glutamyltransferase level is related to adiponectin level in nonalcoholic women without liver disease 688817
Show all pathways known for 2.3.2.2Display the word mapDisplay the reaction diagram Show all sequences 2.3.2.2gamma-glutamyltransferase blood serum GGT activities from 1147 moderate drinkers and 449 abstainers are classified according to body mass index are compared with those of 208 heavy drinkers admitted for detoxification. GGT upper normal limits, defined based on normal weight abstainers are lower than those based on moderate drinkers. The relative increases in GGT activities in male moderate drinkers with overweight (54%) or obesity (125%) exceedes the corresponding changes found in women (25% and 75%, respectively). The BMI-dependent variation on the sensitivity of GGT for correctly classifying heavy drinkers ranges from 29% to 67%. The rates of false-positive values in the subgroups from low to high BMI varies from 0% to 27%, respectively 690044
Show all pathways known for 2.3.2.2Display the word mapDisplay the reaction diagram Show all sequences 2.3.2.2gamma-glutamyltransferase blood serum GGT is closely related with insulin resistance and the increased number of components of metabolic syndrome. Among components of metabolic syndrome, serum GGT may be more associated with dyslipidemia and abnormal glucose tolerance, suggesting that serum GGT has more relationship with hepatic insulin resistance regardless of non-alcoholic fatty liver disease 686311
Show all pathways known for 2.3.2.2Display the word mapDisplay the reaction diagram Show all sequences 2.3.2.2gamma-glutamyltransferase blood serum GGT level has positive correlation with family history of liver disease 677259
Show all pathways known for 2.3.2.2Display the word mapDisplay the reaction diagram Show all sequences 2.3.2.2gamma-glutamyltransferase blood serum GGT levels are increased significantly in Alzheimers disease patients 687197
Show all pathways known for 2.3.2.2Display the word mapDisplay the reaction diagram Show all sequences 2.3.2.2gamma-glutamyltransferase blood serum GSTM1- and GSTM1-/GSTT1- genotypes may be a genetic risk factor for the increase of GGT in Japanese epileptic patients treated with valproic acid patients. It is not possible to clarify whether the GGT increase is caused by valproic acid-induced hepatotoxicity or not 686165
Show all pathways known for 2.3.2.2Display the word mapDisplay the reaction diagram Show all sequences 2.3.2.2gamma-glutamyltransferase blood serum habitual coffee consumption is associated with lower incidence of type II diabetes particularly in those with higher baseline serum GGT levels 686500
Show all pathways known for 2.3.2.2Display the word mapDisplay the reaction diagram Show all sequences 2.3.2.2gamma-glutamyltransferase blood serum high serum gamma-glutamyltransferase is associated with an increased risk of liver cancer 687012
Show all pathways known for 2.3.2.2Display the word mapDisplay the reaction diagram Show all sequences 2.3.2.2gamma-glutamyltransferase blood serum higher serum gamma-glutamyltransferase levels are associated with prehypertension in a nationally representative sample of US adults, free of cardiovascular disease and hypertension 686109
Show all pathways known for 2.3.2.2Display the word mapDisplay the reaction diagram Show all sequences 2.3.2.2gamma-glutamyltransferase blood serum higher serum gamma-glutamyltransferase levels are independently associated with impaired coronary microvascular function in patients with dilated cardiomyopathy 684806
Show all pathways known for 2.3.2.2Display the word mapDisplay the reaction diagram Show all sequences 2.3.2.2gamma-glutamyltransferase blood serum increased GGT activities are independently associated with a more atherogenic lipid profile in general population 686163
Show all pathways known for 2.3.2.2Display the word mapDisplay the reaction diagram Show all sequences 2.3.2.2gamma-glutamyltransferase blood serum presence in plaques of a serum-like gamma-glutamyltransferase protein, indicating that a direct contribution of serum gamma-glutamyltransferase to enzyme activity found within atherosclerotic lesions is possible. Occurrence of gamma-glutamyltransferase-mediated redox reactions within plaque environment might influence plaque progression 684807
Show all pathways known for 2.3.2.2Display the word mapDisplay the reaction diagram Show all sequences 2.3.2.2gamma-glutamyltransferase blood serum serum gamma-glutamyltransferase levels are positively associated with peripheral arterial disease among men (peripheral arterial disease) but not women 684804
Show all pathways known for 2.3.2.2Display the word mapDisplay the reaction diagram Show all sequences 2.3.2.2gamma-glutamyltransferase blood serum serum GGT activity is increased in patients with calcific aortic stenosis. These increases seem to occur in advanced rather than milder forms of calcific aortic valve disease 688133
Show all pathways known for 2.3.2.2Display the word mapDisplay the reaction diagram Show all sequences 2.3.2.2gamma-glutamyltransferase blood serum serum GGT is specifically associated with the visceral fat area, but not with the subcutaneous fat area, suggests that the serum GGT may be useful as a convenient indicator of visceral fat area in the clinical treatment of obesity 686312
Show all pathways known for 2.3.2.2Display the word mapDisplay the reaction diagram Show all sequences 2.3.2.2gamma-glutamyltransferase blood serum serum GGT within its normal range can predict cardiovascular diseases mortality in those aged less than 70 years, but may have limited usefulness for risk assessment in older adults 686498
Show all pathways known for 2.3.2.2Display the word mapDisplay the reaction diagram Show all sequences 2.3.2.2gamma-glutamyltransferase blood serum strong interaction between serum gamma-glutamyltransferase and obesity on the risk of prevalent type 2 diabetes 686146
Show all pathways known for 2.3.2.2Display the word mapDisplay the reaction diagram Show all sequences 2.3.2.2gamma-glutamyltransferase blood serum subjects are divided into four groups according to their level of alcohol consumption: nondrinkers, light drinkers (1-188 ml/week), intermediate drinkers (189-377 ml/week), and heavy drinkers (more than 378 ml/week). The frequency of subjects with an fasting plasma glucose of 110 mg/dl or more rises significantly as alcohol consumption increases, from 6.7% in non-drinkers to 10.1% in intermediate drinkers and 12.1% in heavy drinkers. When only the subjects with a gamma-glutamyltransferase level of less than 40 IU/l are analyzed, no difference is observed in the frequency of subjects with an FPG level of 110 mg/dl or more among the four groups 686313
Display the word mapDisplay the reaction diagram Show all sequences 2.4.1.22lactose synthase blood serum - 488944, 488947
Display the word mapDisplay the reaction diagram Show all sequences 2.4.1.225N-acetylglucosaminyl-proteoglycan 4-beta-glucuronosyltransferase blood serum - 488953
Show all pathways known for 2.4.1.226Display the word mapDisplay the reaction diagram Show all sequences 2.4.1.226N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase blood serum - 488967
Show all pathways known for 2.4.1.226Display the word mapDisplay the reaction diagram Show all sequences 2.4.1.226N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase blood serum fetal bovine serum 488968
Display the word mapDisplay the reaction diagram Show all sequences 2.4.1.69type 1 galactoside alpha-(1,2)-fucosyltransferase blood serum - 489350, 489352
Display the word mapDisplay the reaction diagram Show all sequences 2.4.1.69type 1 galactoside alpha-(1,2)-fucosyltransferase blood serum from AB and mixed secretor phenotype individuals 489349
Display the word mapDisplay the reaction diagram Show all sequences 2.4.1.69type 1 galactoside alpha-(1,2)-fucosyltransferase blood serum of donors of all ABO blood-groups examined, except those of the rare Oh (Bombay) and Bh phenotypes 489348
Display the word mapDisplay the reaction diagram Show all sequences 2.4.2.12nicotinamide phosphoribosyltransferase blood serum similar mRNA expression levels in (fa/fa) Zucker rats (obese) compared to lean Zucker rats (control) as well as in cafeteria diet-fed Wistar rats (diet-induced obesity) compared to standard chow diet-fed Wistar rats (control) 692570
Show all pathways known for 2.4.2.26Display the word mapDisplay the reaction diagram Show all sequences 2.4.2.26protein xylosyltransferase blood serum elevated xylosyltransferase I activities in Pseudoxanthoma elasticum patients 681502
Show all pathways known for 2.4.2.26Display the word mapDisplay the reaction diagram Show all sequences 2.4.2.26protein xylosyltransferase blood serum increased activity of xylosyltransferase I in the blood serum of patients with connective tissue diseases 679274
Show all pathways known for 2.4.2.26Display the word mapDisplay the reaction diagram Show all sequences 2.4.2.26protein xylosyltransferase blood serum patients with osteoarthritis 657789
Show all pathways known for 2.4.2.26Display the word mapDisplay the reaction diagram Show all sequences 2.4.2.26protein xylosyltransferase blood serum XylT2 is predominant 703904
Show all pathways known for 2.4.2.26Display the word mapDisplay the reaction diagram Show all sequences 2.4.2.26protein xylosyltransferase blood serum XylT2 is predominant. XylT levels in serum are approximately 200% higher than those in plasma due in part to XylT released by platelets during blood clotting in vitro. In Xylt2+/+ mice, total serum XylT activity is 42% higher than in plasma. In Xylt2-/- mice, no significant difference between serum and plasma total XylT activity 703904
Show all pathways known for 2.4.2.4Display the word mapDisplay the reaction diagram Show all sequences 2.4.2.4thymidine phosphorylase blood serum presurgery serum from 47 patients with ovarian cancer, and control serum from women with normal ovaries, treated surgically due to nononcological reasons. Significant higher enzyme activity in malignant serum specimen from ovarian cancer patients when compared to the control 658872
Display the reaction diagram Show all sequences 2.4.3.1beta-galactoside alpha-(2,6)-sialyltransferase blood serum level of serum ST6Gal I in patients with chronic active hepatitis is significantly increased compared to that in patients with chronic persistent hepatitis. Serum level of ST6Gal I in hepatitis C patients is correlated with the activity of hepatic inflammation, but not with liver fibrosis 703898
Show all pathways known for 2.6.1.2Display the word mapDisplay the reaction diagram Show all sequences 2.6.1.2alanine transaminase blood serum - 721277
Display the word mapDisplay the reaction diagram Show all sequences 2.7.1.171protein-fructosamine 3-kinase blood serum - 738074
Show all pathways known for 2.7.1.21Display the word mapDisplay the reaction diagram Show all sequences 2.7.1.21thymidine kinase blood serum - 671360, 750551
Show all pathways known for 2.7.2.3Display the word mapDisplay the reaction diagram Show all sequences 2.7.2.3phosphoglycerate kinase blood serum of 10 cancer patients whose serum is tested, 3 of 4 with pancreatic cancer have 65-900% higher levels of PGK1 than that found in normal serum 688148
Display the word mapDisplay the reaction diagram Show all sequences 2.7.3.2creatine kinase blood serum - 721916
Display the word mapDisplay the reaction diagram Show all sequences 2.7.3.2creatine kinase blood serum phenylbutyrate greatly decreases the adriamycin-associated elevations of serum lactate dehydrogenase and creatine kinase activities, two nonspecific widely used cardiac injury markers 686860
Display the word mapDisplay the reaction diagram Show all sequences 3.1.1.111phosphatidylserine sn-1 acylhydrolase blood serum - 753301, 753940
Show all pathways known for 3.1.1.2Display the word mapDisplay the reaction diagram Show all sequences 3.1.1.2arylesterase blood serum - 35213, 35215, 646527, 650953, 664184, 665960, 666183, 677892, 679182, 679306, 749610, 749628, 750345, 750428, 750482, 750483, 750511, 750758, 752150, 752173
Show all pathways known for 3.1.1.2Display the word mapDisplay the reaction diagram Show all sequences 3.1.1.2arylesterase blood serum contains A-type paraoxonase and B-type paraoxonase 646527
Show all pathways known for 3.1.1.2Display the word mapDisplay the reaction diagram Show all sequences 3.1.1.2arylesterase blood serum enzyme activity against the phenylacetate is higher, and phenotype-dependent, only in diabetic patients with type II diabetes mellitus. Less antiatherogenic paraoxonase B allele is more frequent in type II diabetes mellitus than in the healthy population. Their lipid status is more atherogenic, which could indicate a risk of premature atherosclerosis 677411
Show all pathways known for 3.1.1.2Display the word mapDisplay the reaction diagram Show all sequences 3.1.1.2arylesterase blood serum in serum, the esterase is tightly bound to the high density lipoproteins, particularly apo A-l 646509
Show all pathways known for 3.1.1.2Display the word mapDisplay the reaction diagram Show all sequences 3.1.1.2arylesterase blood serum in the blood of Gulf War veterans who developed delayed neurotoxicity symptoms the levels of serum paraoxonase (PON1) isozyme type Q is significantly lower than in the control, unaffected veteran group 646528
Show all pathways known for 3.1.1.2Display the word mapDisplay the reaction diagram Show all sequences 3.1.1.2arylesterase blood serum of A and B phenotypes. Human serum contains a single enzyme with both paraoxonase and arylesterase activities 35212
Show all pathways known for 3.1.1.2Display the word mapDisplay the reaction diagram Show all sequences 3.1.1.2arylesterase blood serum phenylketonuric patients. Paraoxonase/arylesterase activities are strongly related to the dietary control of phenylketonuric patients 679634
Show all pathways known for 3.1.1.2Display the word mapDisplay the reaction diagram Show all sequences 3.1.1.2arylesterase blood serum PON1 activity determined towards the synthetic compounds paraoxon and phenyl acetate reflects no association with markers of oxidative stress 677297
Display the word mapDisplay the reaction diagram Show all sequences 3.1.1.251,4-lactonase blood serum - 650953, 665960, 681264, 749628, 750345, 750428, 750462, 750511, 751389
Display the word mapDisplay the reaction diagram Show all sequences 3.1.1.471-alkyl-2-acetylglycerophosphocholine esterase blood serum - -, 690429, 694940, 716432
Display the word mapDisplay the reaction diagram Show all sequences 3.1.1.471-alkyl-2-acetylglycerophosphocholine esterase blood serum no statistical differences in PAF-AH activity between serologically negative horses, with 740 U/l, and those with residual, 735 U/l, and high antibody titre on leptospirosis, 790 U/l, respectively 713682
Display the reaction diagram Show all sequences 3.1.1.56methylumbelliferyl-acetate deacetylase blood serum autoantibodies detectable in patients with Behcet’s disease (BD, 25%), Vogt-Koyanagi-Harada disease (VKH, 25%), and sarcoidosis (17.6%) 700318
Display the reaction diagram Show all sequences 3.1.1.56methylumbelliferyl-acetate deacetylase blood serum IgG1 autoantibodies detected in mice with experimental autoimmune uveoretinitis 700318
Display the word mapDisplay the reaction diagram Show all sequences 3.1.1.7acetylcholinesterase blood serum activity increases in serum of animal intoxicated by aflatoxins (group B) 757608
Display the word mapDisplay the reaction diagram Show all sequences 3.1.1.8cholinesterase blood serum - 678541, 691094, 691944, 693402
Display the word mapDisplay the reaction diagram Show all sequences 3.1.1.8cholinesterase blood serum the low concentration of BoBChE in serum is explained by limited quantities of an unidentified polyproline-rich protein 750289
Display the word mapDisplay the reaction diagram Show all sequences 3.1.4.39alkylglycerophosphoethanolamine phosphodiesterase blood serum - 679257, 680318
Display the word mapDisplay the reaction diagram Show all sequences 3.1.4.39alkylglycerophosphoethanolamine phosphodiesterase blood serum activity progressively increases throughout pregnancy 700238
Display the word mapDisplay the reaction diagram Show all sequences 3.1.4.50glycosylphosphatidylinositol phospholipase D blood serum - 666244, 668244, 669623
Display the word mapDisplay the reaction diagram Show all sequences 3.1.4.50glycosylphosphatidylinositol phospholipase D blood serum no acitivity in blood serum 682945
Show all pathways known for 3.1.8.1Display the word mapDisplay the reaction diagram Show all sequences 3.1.8.1aryldialkylphosphatase blood serum - 35192, 35208, 35213, 35215, 646527, 650953, 664184, 665960, 666183, 677892, 679182, 679306, 681264, 749628, 750345, 750428, 750482, 750483, 750511, 752150, 752173
Show all pathways known for 3.1.8.1Display the word mapDisplay the reaction diagram Show all sequences 3.1.8.1aryldialkylphosphatase blood serum contains A-type paraoxonase and B-type paraoxonase 646527
Show all pathways known for 3.1.8.1Display the word mapDisplay the reaction diagram Show all sequences 3.1.8.1aryldialkylphosphatase blood serum determination of the distribution of the PON1 192Q/R and -108C/T polymorphisms in a Peruvian population and comparison of the distribution of these polymorphisms with those of other world populations 679530
Show all pathways known for 3.1.8.1Display the word mapDisplay the reaction diagram Show all sequences 3.1.8.1aryldialkylphosphatase blood serum in serum, the esterase is tightly bound to the high density lipoproteins, particularly apo A-l 646509
Results 1 - 100 of 165 > >>
download as CSV
download all results as CSV